Skip to main content
. 2021 Sep 20;12:5536. doi: 10.1038/s41467-021-25551-1

Fig. 5. Thapsigargin suppresses CoV replication in differentiated primary human bronchial epithelial cells.

Fig. 5

a Scheme showing the expansion in a liquid−liquid interphase (LLI) followed by the differentiation at an air-liquid interphase (ALI) of normal human bronchial epithelial cells (NHBE). b Three-dimensional immunofluorescence analysis (z-stacks) of representative NHBE cells stained with antibodies specific for the indicated differentiation markers. Shown is one representative out of two biologically independent experiments. c NHBE cells were left untreated or infected with the indicated CoV (MOI = 3) and treated for up to three days with thapsigargin (0.1 or 1 µM). Supernatants were collected at five time points p.i. and virus titers determined by plaque assay. Data represent three biologically independent experiments using NHBE cells derived from two or three independent donors. Shown are means ± s.d. of technical duplicates. For HCoV-229E and MERS-CoV, cells from donor 1 were plated and differentiated a second time to generate an additional independent experiment (labeled donor 1.2). See Supplementary Fig. 5f for cell viability experiments.